EUVIMEDEUVIMED entdecken
Open Access

Thiazolidinedione Use and Cardiovascular Outcomes in Patients With Type 2 Diabetes Who Underwent Carotid Artery Revascularization

Jun Hwee Kim iD, Jimin Jeon iD, Seok-Jae Heo iD, Tae-Jin Song iD, Minyoul Baik iD, Joonsang Yoo iD, Jinkwon Kim iD

Journal of the American Heart Association · 2025

DOI: 10.1161/jaha.124.037950 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Journal of the American Heart Association, 2025. Verfasst von Jun Hwee Kim und 6 weiteren Autor:innen. Beteiligte Einrichtung: Department of Radiology Yongin Severance Hospital, Yonsei University College of Medicine Yongin Republic of Korea. Hauptthemen laut MEDLINE: Diabetes Mellitus, Type 2, Endarterectomy, Carotid, Hypoglycemic Agents, Thiazolidinediones. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 36 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Thiazolidinediones are oral antidiabetic agents known for their wide‐ranging pleiotropic effects, potentially offering cardiovascular protection. Using a nationwide health claims database in Korea, we evaluated whether thiazolidinedione treatment was associated with long‐term cardiovascular prognosis after carotid revascularization. Methods and Results This retrospective cohort study included patients with type 2 diabetes who underwent carotid endarterectomy or stent insertion in Korea between 2009 and 2020. The use of medications, including thiazolidinediones, was determined from prescription records, identifying exposure to medications within 30 days following carotid revascularization. The primary outcome was the composite occurrence of stroke, myocardial infarction, and all‐cause death following carotid revascularization. A multivariate Cox regression analysis was conducted to assess the primary outcomes. The cohort included 14 220 patients with type 2 diabetes who underwent carotid revascularization (2669 via carotid endarterectomy and 11 551 via carotid stent insertion). Among them, 1034 patients received thiazolidinedione treatment. Over a mean follow‐up period of 4.13±3.14 years, 4087 patients experienced a primary outcome. Thiazolidinedione treatment was significantly associated with a reduced risk of primary outcomes (adjusted hazard ratio [HR], 0.81 [95% CI, 0.71–0.93]; P =0.002). The protective effect of thiazolidinediones was supported in a propensity score–matched analysis comparing thiazolidinedione users with nonusers (HR, 0.81 [95% CI, 0.68–0.95]; P =0.013).

Conclusions

Thiazolidinedione treatment following carotid revascularization was associated with favorable cardiovascular outcomes in patients with type 2 diabetes. Further research is needed to explore the cardioprotective roles of thiazolidinediones in this high‐risk group.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Diabetes Mellitus, Type 2Endarterectomy, CarotidHypoglycemic AgentsThiazolidinedionesCarotid Artery DiseasesEndovascular ProceduresHumansMaleFemaleRetrospective StudiesAgedRepublic of KoreaMiddle AgedStentsRisk FactorsMyocardial InfarctionTreatment OutcomeTime FactorsRisk AssessmentStroke

Stichwörter der Autor:innen

carotid arterydiabetesmyocardial infarctionstrokethiazolidinediones

Substanzen

Hypoglycemic AgentsThiazolidinediones

Autor:innen und Institutionen

  • Department of Radiology Yongin Severance Hospital, Yonsei University College of Medicine Yongin Republic of Korea.
  • Department of Neurology Yongin Severance Hospital, Yonsei University College of Medicine Yongin Republic of Korea.
  • Biostatistics Collaboration Unit, Department of Biomedical Systemic Informatics Yonsei University College of Medicine Seoul Republic of Korea.
  • Department of Neurology Seoul Hospital Ewha Womans University College of Medicine Seoul Republic of Korea.

ORCID-Profile: Jun Hwee Kim, Jimin Jeon, Seok-Jae Heo, Tae-Jin Song, Minyoul Baik, Joonsang Yoo, Jinkwon Kim

Zitieren

APA

Kim, J. H., Jeon, J., Heo, S. J., Song, T. J., Baik, M., Yoo, J., & Kim, J. (2025). Thiazolidinedione Use and Cardiovascular Outcomes in Patients With Type 2 Diabetes Who Underwent Carotid Artery Revascularization. Journal of the American Heart Association. https://doi.org/10.1161/jaha.124.037950

Vancouver

Kim JH, Jeon J, Heo SJ, Song TJ, Baik M, Yoo J, et al. Thiazolidinedione Use and Cardiovascular Outcomes in Patients With Type 2 Diabetes Who Underwent Carotid Artery Revascularization. Journal of the American Heart Association. 2025. doi:10.1161/jaha.124.037950

BibTeX
@article{Kim2025,
  author = {Kim, Jun Hwee and Jeon, Jimin and Heo, Seok-Jae and Song, Tae-Jin and Baik, Minyoul and Yoo, Joonsang and Kim, Jinkwon},
  title = {Thiazolidinedione Use and Cardiovascular Outcomes in Patients With Type 2 Diabetes Who Underwent Carotid Artery Revascularization},
  journal = {Journal of the American Heart Association},
  year = {2025},
  doi = {10.1161/jaha.124.037950}
}
Kostenlos starten →